Predictive Oncology Inc. (POAI) - EV/EBITDA Multiple
Predictive Oncology (POAI) demonstrates resilience to market volatility, driven by demand for advanced medtech and the success of clinical trials. This chart confirms the market price, where the EV/EBITDA multiple stands at 0.00, helping to track these trends. The company is implementing sustainable AI solutions to combat cancer, thereby reducing laboratory waste. Management is betting on global alliances with pharma behemoths to monetize its digital platforms.
Analytical breakdowns for predictive-oncology.com (POAI)
- stock price and consensus target price:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Predictive Oncology|POAI - Long-Term Loans to Capital Ratio|Short-Term Debt to Equity Predictive Oncology Inc.|POAI - Aggregate Debt Obligations|Debt to Book Value POAI|POAI - Company Long-Term Debts|Company Short-Term Debt Predictive Oncology|Quick Ratio predictive-oncology.com
- business earnings and investment ratios data:
POAI - Company Net Income|Expected Profit Predictive Oncology|POAI - Price to Earnings Multiple|Projected Price to Earnings Predictive Oncology Inc.|POAI - Company Value to Earnings Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization POAI|POAI - Operating income before deduction of amortization|Earnings per share for the last twelve months Predictive Oncology|POAI - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months predictive-oncology.com|POAI - Earnings per share increase in current year|Earnings growth forecast for next year Predictive Oncology
Summary company analysis:Predictive Oncology Corp (POAI)
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before interest and taxes, allowing for the determination of an asset's undervaluation regardless of its capital structure. By analyzing the dynamic EV/EBITDA value of Predictive Oncology (POAI), an investor can assess the cost management efficiency of Predictive Oncology (POAI) amid its dependence on the R&D budgets of pharma behemoths and the demand for its AI platforms.
Competitors of Predictive Oncology
Intuitive Surgical Inc - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation DHR|Becton Dickinson & Co - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio steris.com STE|West Pharmaceutical Services, Inc. (WST) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BAX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Masimo Personal Health|Stevanato Group Corp (STVN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TFX (Teleflex Incorporated)|Enterprise Value to Operating Income Before Depreciation Ratio MMSI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Envista NVST|Business Value to Operating Income Before Depreciation ICUI|XRAY: Enterprise Value to EBITDA Ratio|LMAT - EV/EBITDA Multiple|AtriCure, Inc. (ATRC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio staar.com|NAGE (ChromaDex Corp.) - EV/EBITDA Multiple|Company Value to EBITDA ZimVie Inc ZIMV|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AngioDynamics Corp (ANGO)|Cerus Inc - Enterprise Value to Operating Income Before Depreciation|Alpha Teknova, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MGRM (monogramorthopedics.com)|STSS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio InfuSystem Holdings INFU|Utah Medical (UTMD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio KRMD (KORU Medical)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nyxoah S.A.|MBOT: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PDEX|ZTEK - Company Value to EBITDA|EV/EBITDA Multiple ELUT (Elutia Corp)|MLSS: Enterprise Value to Operating Income Before Depreciation|NEXGEL, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Retractable Technologies RVP|HBIO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Femasys Inc|Enterprise Value to EBITDA Ratio MHUA|CJMB (Callan JMB Corp) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ATRI|Total Company Value to Operating Income Before Depreciation Ratio neurometrix.com
